Randomisation and masking
ENS@T adrenocortical carcinoma
After consent, patients were randomly assigned (1:1) in a parallel group design to receive either adjuvant mitotane or to active surveillance alone, and stratified for stage (I–II All consecutive patients at 14 study centres fulfilling the eligibility criteria of the ADIUVO trial who refused randomisation and agreed on data collection via the ENS@T adrenocortical carcinoma registry were included prospectively in the ADIUVO Observational study (